gp96

BIOLOGICAL3 trials

Sponsors

Cure&Sure Biotech Co., LTD

Conditions

GliomaGlioma of BrainLiver Cancer

Phase 1

Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96

CompletedNCT02122822

Cure&Sure Biotech Co., LTDGlioma

Start: 2013-07-31End: 2017-05-31Updated: 2017-11-17

Phase 2

A Large-scale Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96

Cure&Sure Biotech Co., LTDGlioma of Brain

Start: 2019-08-21End: 2024-08-20Target: 150Updated: 2020-03-12

GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Liver Cancer

Cure&Sure Biotech Co., LTDLiver Cancer

Start: 2019-12-19End: 2023-08-05Target: 80Updated: 2019-12-20

Related Papers

Low MxA Expression Predicts Better Immunotherapeutic Outcomes in Glioblastoma Patients Receiving Heat Shock Protein Peptide Complex 96 Vaccination

Frontiers in Oncology2022-07-125 citations

Resection of Noncontrast-Enhancing Regions Deteriorated the Immunotherapeutic Efficacy of HSPPC-96 Vaccination in Treating Glioblastoma

Frontiers in Oncology2022-05-181 citations

T cell receptor repertoire as a prognosis marker for heat shock protein peptide complex-96 vaccine trial against newly diagnosed glioblastoma

OncoImmunology2020-01-0126 citations

Heat shock protein peptide complex-96 vaccination for newly diagnosed glioblastoma: a phase I, single-arm trial.

2018-05-1756 citations